Kura Oncology (NASDAQ:KURA) Given Buy Rating at HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 418.81% from the company’s previous close. HC Wainwright also issued estimates for Kura Oncology’s Q1 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

Several other equities analysts have also weighed in on the stock. Wedbush raised their price objective on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Bank of America reduced their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. Finally, Jefferies Financial Group reduced their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Performance

Shares of KURA opened at $7.71 on Thursday. The firm has a 50-day moving average price of $8.16 and a 200 day moving average price of $13.88. The firm has a market capitalization of $599.56 million, a PE ratio of -3.27 and a beta of 0.78. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, sell-side analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after purchasing an additional 84,563 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology in the fourth quarter worth $436,000. Moody Aldrich Partners LLC grew its stake in shares of Kura Oncology by 42.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after acquiring an additional 42,712 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after acquiring an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Kura Oncology in the fourth quarter worth $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.